Drug Profile
LY 3143921
Alternative Names: LY-3143921; LY3143921 hydrateLatest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Cancer Research UK; Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action CDC7 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Oct 2023 LY 3143921 is still in phase-I development in Solid-tumours (Late-stage disease, Refractory metastatic disease) in United Kingdom (PO)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Refractory metastatic disease) in United Kingdom (PO)
- 03 Jun 2022 Efficacy, adverse events and pharmacokinetics data from a phase I CR-UX trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)